Literature DB >> 9921983

Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability.

E M Swisher1, S Peiffer-Schneider, D G Mutch, T J Herzog, J S Rader, A Elbendary, P J Goodfellow.   

Abstract

BACKGROUND: The correlation between tumor microsatellite instability (MSI) and the accumulation of mutations in KRAS2 and TP53 is uncertain. The authors evaluated the TP53 and KRAS2 genes for mutations in sporadic endometrial carcinomas with microsatellite instability (MSI) and matched MSI negative controls to determine whether defective DNA mismatch repair impacts the patterns of mutations in two genes known to be involved in endometrial tumorigenesis.
METHODS: Twenty-five MSI positive endometrial tumors were matched for prognostic factors with 25 MSI negative tumors. Mutations in codon 12 and 13 of KRAS2 were assessed using a polymerase chain reaction (PCR) restriction assay. Mutations in codon 61 of KRAS2 and exons 5-8 of TP53 were evaluated using PCR amplification and single strand conformation variant (SSCV) analysis. All variants were subjected to direct DNA sequencing.
RESULTS: KRAS2 and TP53 mutations were identified with equal frequency in the MSI positive and MSI negative groups. For TP53, the authors identified 5 mutations (20%) in the MSI positive specimens compared with 8 (32%) in the MSI negative group. For KRAS2, there were identified 8 mutations (32%) in the MSI positive specimens compared with 7 (28%) in the MSI negative tumors. The mutational spectra evident from sequence analysis of TP53 and KRAS2 variants were similar between MSI negative and MSI positive tumors. MSI negative tumors were more likely to have mutations in both KRAS2 and TP53 than MSI positive tumors, which were rarely mutant in both genes (P=0.046).
CONCLUSIONS: Although the overall frequency of mutations in TP53 and KRAS2 is similar, MSI positive tumors are less likely to have mutations in both genes than MSI negative sporadic endometrial carcinomas. MSI positive and MSI negative endometrial carcinomas may arise through distinct genetic pathways.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9921983     DOI: 10.1002/(sici)1097-0142(19990101)85:1<119::aid-cncr17>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Alteration of the k-ras gene expression in atypical and nonatypical hyperplastic endometrium.

Authors:  Narges Izadi-Mood; Soheila Sarmadi; Behzad Rostamnasl
Journal:  Iran J Cancer Prev       Date:  2013

2.  K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis.

Authors:  G L Mutter; H Wada; W C Faquin; T Enomoto
Journal:  Mol Pathol       Date:  1999-10

Review 3.  Molecular pathogenesis of endometrial and ovarian cancer.

Authors:  Melissa A Merritt; Daniel W Cramer
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

4.  Genetics of endometrial cancers.

Authors:  Tsuyoshi Okuda; Akihiko Sekizawa; Yuditiya Purwosunu; Masaaki Nagatsuka; Miki Morioka; Masaki Hayashi; Takashi Okai
Journal:  Obstet Gynecol Int       Date:  2010-04-08

5.  Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract.

Authors:  Jelena Mirkovic; Lynette M Sholl; Elizabeth Garcia; Neal Lindeman; Laura MacConaill; Michelle Hirsch; Paola Dal Cin; Melissa Gorman; Justine A Barletta; Marisa R Nucci; W Glenn McCluggage; Brooke E Howitt
Journal:  Mod Pathol       Date:  2015-09-04       Impact factor: 7.842

Review 6.  Wnt/Β-catenin and sex hormone signaling in endometrial homeostasis and cancer.

Authors:  Yongyi Wang; Marten van der Zee; Riccardo Fodde; Leen J Blok
Journal:  Oncotarget       Date:  2010-11

7.  FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.

Authors:  Sara A Byron; Michael Gartside; Matthew A Powell; Candice L Wellens; Feng Gao; David G Mutch; Paul J Goodfellow; Pamela M Pollock
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.